BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38464081)

  • 1. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
    He T; Cheng C; Qiao Y; Cho H; Young E; Mannan R; Mahapatra S; Miner SJ; Zheng Y; Kim N; Zeng VZ; Wisniewski JP; Hou S; Jackson B; Cao X; Su F; Wang R; Chang Y; Kuila B; Mukherjee S; Dukare S; Aithal KB; D S S; Abbineni C; Lyssiotis CA; Parolia A; Xiao L; Chinnaiyan AM
    bioRxiv; 2024 Mar; ():. PubMed ID: 38464081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
    He T; Cheng C; Qiao Y; Cho H; Young E; Mannan R; Mahapatra S; Miner SJ; Zheng Y; Kim N; Zeng VZ; Wisniewski JP; Hou S; Jackson B; Cao X; Su F; Wang R; Chang Y; Kuila B; Mukherjee S; Dukare S; Aithal KB; D S S; Abbineni C; Vaishampayan U; Lyssiotis CA; Parolia A; Xiao L; Chinnaiyan AM
    Proc Natl Acad Sci U S A; 2024 Apr; 121(15):e2322563121. PubMed ID: 38557192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies.
    He T; Xiao L; Qiao Y; Klingbeil O; Young E; Wu XS; Mannan R; Mahapatra S; Eyunni S; Ching-Yi Tien J; Wang X; Zheng Y; Kim N; Zheng H; Hou S; Su F; Miner SJ; Mehra R; Cao X; Abbineni C; Samajdar S; Ramachandra M; Parolia A; Vakoc CR; Chinnaiyan AM
    bioRxiv; 2024 May; ():. PubMed ID: 38328238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.
    Xiao L; Parolia A; Qiao Y; Bawa P; Eyunni S; Mannan R; Carson SE; Chang Y; Wang X; Zhang Y; Vo JN; Kregel S; Simko SA; Delekta AD; Jaber M; Zheng H; Apel IJ; McMurry L; Su F; Wang R; Zelenka-Wang S; Sasmal S; Khare L; Mukherjee S; Abbineni C; Aithal K; Bhakta MS; Ghurye J; Cao X; Navone NM; Nesvizhskii AI; Mehra R; Vaishampayan U; Blanchette M; Wang Y; Samajdar S; Ramachandra M; Chinnaiyan AM
    Nature; 2022 Jan; 601(7893):434-439. PubMed ID: 34937944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection.
    Wei J; Patil A; Collings CK; Alfajaro MM; Liang Y; Cai WL; Strine MS; Filler RB; DeWeirdt PC; Hanna RE; Menasche BL; Ökten A; Peña-Hernández MA; Klein J; McNamara A; Rosales R; McGovern BL; Luis Rodriguez M; García-Sastre A; White KM; Qin Y; Doench JG; Yan Q; Iwasaki A; Zwaka TP; Qi J; Kadoch C; Wilen CB
    Nat Genet; 2023 Mar; 55(3):471-483. PubMed ID: 36894709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment.
    Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM
    Neoplasia; 2020 Feb; 22(2):111-119. PubMed ID: 31931431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ATPase module of mammalian SWI/SNF family complexes mediates subcomplex identity and catalytic activity-independent genomic targeting.
    Pan J; McKenzie ZM; D'Avino AR; Mashtalir N; Lareau CA; St Pierre R; Wang L; Shilatifard A; Kadoch C
    Nat Genet; 2019 Apr; 51(4):618-626. PubMed ID: 30858614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.
    de Miguel FJ; Gentile C; Feng WW; Silva SJ; Sankar A; Exposito F; Cai WL; Melnick MA; Robles-Oteiza C; Hinkley MM; Tsai JA; Hartley AV; Wei J; Wurtz A; Li F; Toki MI; Rimm DL; Homer R; Wilen CB; Xiao AZ; Qi J; Yan Q; Nguyen DX; Jänne PA; Kadoch C; Politi KA
    Cancer Cell; 2023 Aug; 41(8):1516-1534.e9. PubMed ID: 37541244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer.
    Hung CL; Liu HH; Fu CW; Yeh HH; Hu TL; Kuo ZK; Lin YC; Jhang MR; Hwang CS; Hsu HC; Kung HJ; Wang LY
    EBioMedicine; 2023 Apr; 90():104500. PubMed ID: 36893587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors - a review of patent literature from 2019-June 2023.
    Lee ECY; Reichl KD; Gopalsamy A
    Expert Opin Ther Pat; 2024 Apr; 34(4):211-229. PubMed ID: 38742308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.
    Han X; Zhao L; Xiang W; Qin C; Miao B; McEachern D; Wang Y; Metwally H; Wang L; Matvekas A; Wen B; Sun D; Wang S
    J Med Chem; 2021 Sep; 64(17):12831-12854. PubMed ID: 34431670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design.
    Farnaby W; Koegl M; Roy MJ; Whitworth C; Diers E; Trainor N; Zollman D; Steurer S; Karolyi-Oezguer J; Riedmueller C; Gmaschitz T; Wachter J; Dank C; Galant M; Sharps B; Rumpel K; Traxler E; Gerstberger T; Schnitzer R; Petermann O; Greb P; Weinstabl H; Bader G; Zoephel A; Weiss-Puxbaum A; Ehrenhöfer-Wölfer K; Wöhrle S; Boehmelt G; Rinnenthal J; Arnhof H; Wiechens N; Wu MY; Owen-Hughes T; Ettmayer P; Pearson M; McConnell DB; Ciulli A
    Nat Chem Biol; 2019 Jul; 15(7):672-680. PubMed ID: 31178587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong
    Yang L; Tu W; Huang L; Miao B; Kaneshige A; Jiang W; Leng L; Wang M; Wen B; Sun D; Wang S
    J Med Chem; 2023 Aug; 66(15):10761-10781. PubMed ID: 37523716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
    Cantley J; Ye X; Rousseau E; Januario T; Hamman BD; Rose CM; Cheung TK; Hinkle T; Soto L; Quinn C; Harbin A; Bortolon E; Chen X; Haskell R; Lin E; Yu SF; Del Rosario G; Chan E; Dunlap D; Koeppen H; Martin S; Merchant M; Grimmer M; Broccatelli F; Wang J; Pizzano J; Dragovich PS; Berlin M; Yauch RL
    Nat Commun; 2022 Nov; 13(1):6814. PubMed ID: 36357397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting androgen receptor degradation with PROTACs from bench to bedside.
    Jia X; Han X
    Biomed Pharmacother; 2023 Feb; 158():114112. PubMed ID: 36508999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.
    Abou Alaiwi S; Nassar AH; Xie W; Bakouny Z; Berchuck JE; Braun DA; Baca SC; Nuzzo PV; Flippot R; Mouhieddine TH; Spurr LF; Li YY; Li T; Flaifel A; Steinharter JA; Margolis CA; Vokes NI; Du H; Shukla SA; Cherniack AD; Sonpavde G; Haddad RI; Awad MM; Giannakis M; Hodi FS; Liu XS; Signoretti S; Kadoch C; Freedman ML; Kwiatkowski DJ; Van Allen EM; Choueiri TK
    Cancer Immunol Res; 2020 Aug; 8(8):1075-1084. PubMed ID: 32321774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Interaction of SWI/SNF with the Ribosome Regulates Translation and Confers Sensitivity to Translation Pathway Inhibitors in Cancers with Complex Perturbations.
    Ulicna L; Kimmey SC; Weber CM; Allard GM; Wang A; Bui NQ; Bendall SC; Crabtree GR; Bean GR; Van Rechem C
    Cancer Res; 2022 Aug; 82(16):2829-2837. PubMed ID: 35749589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers.
    Chabanon RM; Morel D; Postel-Vinay S
    Semin Cancer Biol; 2020 Apr; 61():180-198. PubMed ID: 31568814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biallelic germline and somatic mutations in malignant mesothelioma: multiple mutations in transcription regulators including mSWI/SNF genes.
    Yoshikawa Y; Sato A; Tsujimura T; Otsuki T; Fukuoka K; Hasegawa S; Nakano T; Hashimoto-Tamaoki T
    Int J Cancer; 2015 Feb; 136(3):560-71. PubMed ID: 24916674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer.
    Duplaquet L; So K; Ying AW; Li X; Li Y; Qiu X; Li R; Singh S; Wu XS; Liu Q; Qi J; Somerville TDD; Heiling H; Mazzola E; Lee Y; Zoller T; Vakoc CR; Doench JG; Forrester WC; Abrams T; Long HW; Niederst MJ; Kadoch C; Oser MG
    bioRxiv; 2024 Jan; ():. PubMed ID: 38328215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.